Every material Form 8-K Oruka Therapeutics, Inc. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Oruka Therapeutics reported Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001 in moderate-to-severe plaque psoriasis. In the 600 mg group, 61% of patients reached PASI 100, the primary endpoint, versus 0% on placebo (p<0.0001), and the company plans to start Phase 3 trials in the first half of 2027 using that dose. The company also reported that cash, equivalents and marketable securities were $1.1 billion as of June 30, 2026.
61% of high-dose (600 mg) patients achieved PASI 100 at Week 16, versus 0% on placebo (p<0.0001); 86% achieved PASI 90 and IGA 0/1.
Treatment-emergent adverse events occurred in 39% of high-dose patients and 43% of placebo patients; no serious TEAEs occurred in the high-dose group.
Phase 3 trials are planned to start in the first half of 2027 with the 600 mg dose, subject to regulatory interactions.
52-week EVERLAST-A results are expected in December 2026; cash of $1.1 billion as of June 30, 2026 is expected to fund operations through an anticipated BLA filing.
Oruka Therapeutics said Todd Edwards began work as its Chief Commercial Officer on August 24, 2026, under an offer letter dated July 22, 2026. Edwards previously held commercial roles at Arcutis Biotherapeutics and Incyte, and his pay package includes a $525,000 base salary, a 40% target bonus and equity grants. The appointment fills a senior commercial role, and the filing discloses the severance terms that apply if his employment ends.
Base salary of $525,000 with a discretionary bonus targeted at 40% of base salary
Stock option for 20,000 shares and RSUs for 100,000 shares, with 25% vesting on August 24, 2027
Signing bonus of $200,000, payable within 30 days of starting employment
Severance of 12 months' base salary without a change in control; 1.0 times base salary plus target bonus if termination occurs within three months before or 12 months after a change in control
Oruka Therapeutics reported second quarter 2026 results with a net loss of $41.2 million, up from $24.6 million a year earlier, as research and development and general and administrative expenses rose. The company had $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026, which it says will fund operations through an anticipated BLA filing for ORKA-001. The filing also updated pipeline timing, including Week 28 EVERLAST-A data expected at the end of the third quarter of 2026.
Net loss was $41.2 million for Q2 2026 versus $24.6 million for Q2 2025.
R&D expenses rose to $43.3 million from $24.1 million; G&A expenses rose to $6.9 million from $4.3 million.
Other income, net was $8.9 million, driven mainly by interest on higher cash and marketable securities.
EVERLAST-B Week 16 data is now expected in Q4 2026, and ORCA-SURGE Week 16 data is now expected in Q1 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Oruka Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →